ID   A2780 PTX(4)
AC   CVCL_C0D6
SY   A2780 PTX (4); A/4 PTX-63d; A/4PTX-63d
DR   cancercelllines; CVCL_C0D6
DR   CancerTools; 160729
DR   GEO; GSM4845009
DR   GEO; GSM4845010
DR   Wikidata; Q112927041
DR   Ximbio; 160729
RX   Patent=PL420318A1;
RX   PubMed=33287223;
WW   https://portal.ichb.pl/commercialization-of-model-for-drug-resistant-cancer-cells/
CC   Population: African American.
CC   Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
CC   Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0134 ! A2780
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 05-10-23; Version: 5
//
RX   Patent=PL420318A1;
RA   Szenajch J., Goralski M., Handschuh L., Siatkowski I., Szabelska-Beresewicz A.,
RA   Swiercz A., Zyprych-Walczak J.;
RT   "Human ovarian cancer cell culture model for paclitaxel-induced inverse
RT   resistance to paclitaxel and cisplatin and use thereof.";
RL   Patent number PL420318A1, 17-Jun-2019.
//
RX   PubMed=33287223; DOI=10.3390/ijms21239218;
RA   Szenajch J., Szabelska-Beresewicz A., Swiercz A., Zyprych-Walczak J.,
RA   Siatkowski I., Goralski M., Synowiec A., Handschuh L.;
RT   "Transcriptome remodeling in gradual development of inverse resistance
RT   between paclitaxel and cisplatin in ovarian cancer cells.";
RL   Int. J. Mol. Sci. 21:9218.1-9218.30(2020).
//